Metric Finance
LearnFAQ
LearnFAQ

Learn / VOR

NASDAQ: VOR

Vor Biopharma (VOR) stock, explained like you're 5

Vor Biopharma trades on the Nasdaq under the ticker VOR. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 1.2 billion dollars.

Ticker
VOR
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Small cap, about 1.2 billion dollars

Is Vor Biopharma a small, medium or large cap company?

No. Vor Biopharma is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 1.2 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Vor Biopharma makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves VOR stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Vor Biopharma Inc. (VOR) stock price, news, quote and history (Yahoo Finance Australia)
  • VOR Nov 2026 35.000 call (VOR261120C00035000) stock price, news, quote and history (Yahoo Finance UK)
  • VOR Oct 2026 25.000 put (VOR261016P00025000) interactive stock chart (Yahoo Finance UK)
  • VOR Nov 2026 35.000 put (VOR261120P00035000) interactive stock chart (Yahoo Finance UK)
  • VOR Nov 2026 35.000 put (VOR261120P00035000) stock historical prices and data (Yahoo Finance UK)

Follow VOR in your daily brief

Each trading day at 5 PM ET we post what happened to Vor Biopharma and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow VOR

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Vor Biopharma stock

What does Vor Biopharma do?

Vor Biopharma trades on the Nasdaq under the ticker VOR. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 1.2 billion dollars.

What is the ticker symbol for Vor Biopharma?

Vor Biopharma trades under the ticker VOR on the Nasdaq.

What is Vor Biopharma's market cap?

Vor Biopharma is a small cap stock with a market cap of about 1.2 billion dollars.

How does Vor Biopharma make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves VOR stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow VOR stock every day?

Add VOR to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow VOR daily

A free brief on Vor Biopharma and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare VOR: VOR vs ARGX, VOR vs RVMD, VOR vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed